Immunotherapy for pancreatic cancer - Science driving clinical progress

Nature Reviews Cancer

Volumn 5, Issue 6, 2005, Pages 459-467

  Laheru, Dan ^a   Jaffee, Elizabeth M ^b  

^a Department of Medical Oncology ^*  (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; VASCULOTROPIN INHIBITOR;

CANCER MODEL; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; RASH; REVIEW; SIGNAL TRANSDUCTION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 20344407571     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1630     Document Type: Review

References (108)

1. Evans, D. B., Abbruzzese, J. L. & Willett, C. G. in Principles and Practice of Oncology 6th edn (ed. DeVita, V. T.) 1126-1161 (J. B. Lippincott, Philadelphia, 2001).
2. Li, D. et al. Pancreatic cancer. Lancet 363, 1049-1057 (2004).
3. Spratlin, J. et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 10, 6956-6961 (2004).
4. Laheru, D., Biedrzycki, B. & Jaffee, E. M. Immunologic approaches to the management of pancreatic cancer. Cancer J. 7, 324-337 (2001).
5. Pardoll, D. & Allison, J. Cancer Immunotherapy: breaking the barriers to harvest the crop. Nature Med. 10, 887-892 (2004).
6. Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10, 909-915 (2004).
7. Restifo, N. P. et al. Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J. Immunol. 14, 182-190 (1993).
8. Ganss, R. & Hanahan, D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res. 58, 4673-4681 (1998).
9. Wang, T. et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Med. 10, 48-54 (2004).
10. Oyama, T. et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J. Immunol. 160, 1224-1232 (1998).
11. Ohm, J. E. & Carbone, D. P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. 23, 263-272 (2001).
12. Bellone, G. et al. Tumor-associated transforming growth factor β and interieukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patrients. Am. J. Pathol. 155, 537-547 (1999).
13. Carreno, B. M. & Collins, M. BTLA: a new inhibitory receptor with a B7-like ligand. Trends Immunol. 24, 524-527 (2003).
14. Sica, G. L. et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18, 849-861 (2003).
15. Coyle, A. J. & Gutierrez-Ramos, J. C. The expanding B7 superfamily: increasing complexity in co-stimulatory signals regulating T cell function. Nature Immunol. 2, 203-209 (2001).
16. Schwartz, R. H. T cell anergy. Annu. Rev. Immunol. 21, 305-334 (2003).
17. Greenwald, R. J. et al. CTLA-4 regulates induction of anergy in vivo. Immunity 14, 145-155 (2001).
18. Chen, L. Co-inhibitory molecules of the B7-CD28 family in the control of T cell immunity. Nature Rev. Immun. 4, 336-347 (2004). Summarizes the B7 receptor family on APCs and their role in immune regulation.
19. Schwartz, R. H. T cell anergy. Annu. Rev. Immunol. 21, 305-334 (2003).
20. Walunas, T. L., Bakker, C. Y. & Bluestone, J. A. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183, 2541-2550 (1996).
21. Greenwald, R. J. et al. CTLA-4 regulates induction of anergy in vivo. Immunity 14, 145-155 (2001).
22. Slavik, J. M., Hutchcroft, J. E. & Bierer, B. E. CD28/CTLA-4 and CD80/86 families: signaling and function. Immunol. Res. 19, 1-24 (1999).
23. Greenfeld, E. A., Nguyen, K. A. & Kuchroo, V. K. CD28/B7 co-stimulation: a review. Crit. Rev. Immunol. 18, 389-418 (1998).
24. Najafian, N. & Khoury, S. J. T cell costimulatory pathways: blockade for autoimmunity. Expert Opin. Biol. Ther. 3, 227-236 (2003).
25. Carreno, B. M. & Collins, M. The B7 family of ligands and its receptors: new pathways for co-stimulaton inhibition of immune responses. Annu. Rev. Immunol. 20, 29-53 (2002)
26. Dong, H. & Chen, L. B7-H1 pathway and its role in the evasion of tumor immunity. J. Mol. Med. 81, 281-287 (2003).
27. Okazaki, T., Iwai, Y. & Honjo, T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr. Opin. Immunol. 14, 779-782 (2002).
28. Agata, Y. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765-772 (1996).
29. Khoury, S. J. & Sayegh, M. H. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 20, 529-538 (2004). Succinctly describes the complex interaction of T cells and APCs and their relationship in defining immune regulation.
30. Liang, S. C. et al. Regulation of PD-1, PD-L1 ,PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33, 2706-2716 (2003). Describes the relationship and role of the programmed death receptors and immune regulation.
31. Ungefroren, H. et al. Immunological escape mechanisms in pancreatic carcinoma. Ann. NY Acad. Sci. 880, 243-251 (1999).
32. Kornmann, M., Ishiwata, T., Kleef, J., Beger, H. G. & Korc, M. Fas and Fas-ligand expression in human pancreatic cancer. Ann. Surg. 231, 368-379 (2000).
33. Elnemr, A. et al. Human pancreatic cancer cells express non functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape. Int. J. Oncol. 18, 33-39 (2001). Describes the association between the death receptor FAS ligand and pancreatic cancer.
34. Von Bernstorff, W. et al. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of Fas ligand. Surgery 125, 73-84 (1999).
35. Ungefroren, H. et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas mediated apoptosis. Cancer Res. 58, 1741-1749 (1998).
36. Elhalel, M. D. et al. CTLA-4. FasL induces alloantigen-specific hyporesponsiveness. J. Immunol. 170, 5842-5850 (2003).
37. Ito, D. et al. Chronic exposure of transforming growth factor β1 confers a more aggressive tumor phenotype through down-regulation of p21 (WAF1/CIP1) in conditionally immortalized pancreatic epithelial cells. Surgery 136, 364-374 (2004).
38. 1 expression metastatic capability of human pancreatic cancer. Oncology 65, 167-173 (2003).
39. Duda, D. G. et al. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene 22, 6857-6864 (2003).
40. Masui, T. et al. Expression of IL-6 receptor in pancreatic cancer: involvement in VEGF induction. Anticancer Res. 22, 4093-4100 (2002).
41. Bellone, G. et al. Tumor-associated transforming growth factor β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am. J. Pathol. 155, 537-547 (1999).
42. Wahl, S. M. & Chen, W. TGF-β: how tolerant can it be? Immunol. Res. 28, 167-179 (2003).
43. Blumberg, R. S. et al. Structure of the T cell antigen receptor: evidence for two CD3 ε subunits in the T cell receptor-CD3 complex. Proc. Natl Acad. Sci. USA 87, 7220-7224 (1990).
44. Clevers, H. The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu. Rev. Immunol. 6, 629-662 (1998).
45. Gold, D. P. et al. Evolutionary relationship between the T3 chain of the T-cell receptor complex and the immunoglobulin supergene family. Proc. Natl Acad. Sci. USA 64, 7649-7653 (1987).
46. Wegener, A. M. K. et al. The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules. Cell 68, 83-95 (1992).
47. Klausner, R. D. & Samelson, L. E. T cell antigen receptor activation pathways: the tyrosine kinase connection. Cell 64, 875-878 (1991)
48. Irving, B. A. & Weiss, A. The cyloplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor associated signal transduction pathways. Cell 64, 891-901 (1991). Describes the regulation of the ζ chain of the T-cell receptor and its important role in immune regulation.
49. Samelson, L. E., Patel, M. D., Weissman, A. M., Harford, J. B. & Klausner, R. D. Antigen activation of murine T cells induces tyrosine phosphorylation of a polypeptide associated with the T cell antigen receptor. Cell 46, 1083-1090 (1986).
50. Siegel, J. N., Klausner, R. D., Rapp, U. R. & Samelson, L. E. T cell receptor engagement stimulates c-raf associated kinase activity via a protein kinase C dependent pathway. J. Biol. Chem. 265, 18472-18480 (1990).
51. Schmielau, J., Nalesnik, M. A. & Finn, O. J. Suppressed T-cell receptor ζ chain expression and cytokine production in pancreatic cancer patients. Clin. Cancer Res. 7, S933-S939 (2001).
52. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994).
53. Jenkins, M. K. & Schwartz, R. H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165, 302-319 (1987).
54. Loke, P. & Allison, J. P. Emerging mechanisms of immune regulation-the extended B7 family and regulatory cells. Arthritis Res. Ther. 6, 208-214 (2004).
55. Sugamura, K., Ishii, N. & Weinberg, A. D. Therapeutic targeting of the effector T cell co-stimulatory molecule OX40. Nature Rev. Immunol. 4, 420-431 (2004).
56. Lane, P. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells. J. Exp. Med. 191, 201-206 (2000).
57. Eliopoulos, A. G. & Young, L. S. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol. 4, 360-367 (2004).
58. Ohm, J. E. et al. VEGF inhibits T cell development and may contribute to tumor induced immune suppression. Blood 101, 4878-4886 (2003). Characterizes the association of VEGF expression and depressed T-cell function in cancer.
59. Sharma, S. et al. Tumor cyclooxygenase 2 dependent suppression of dendritic cell function. Clin. Cancer Res. 9, 961-968 (2003).
60. Sombroek, C. C. et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168, 4333-4343 (2002).
61. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886 (2003).
62. + immunoregulatory T cells: central players in the arena of peripheral tolerance. Sem. Immunol. 16, 81-88 (2004).
63. Liyanage, U. K. et al. Prevalence of regulatory T cells is increased in peripheral blood tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756-2761 (2002).
64. Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10, 942-949 (2004).
65. Mendelsohn, J. & Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6565 (2000).
66. Schwarte-Waldhoff, I., Volpert, O. V. & Bouck, N. P. SMAD4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc. Natl Acad. Sci. USA 97, 9624-9629 (2000).
67. Nair, S. et al. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102, 964-971 (2003).
68. Gabrilovich, D. I. et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5, 2963-2970 (1999)
69. Xiong, H. Q. et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic Cancer: a multicenter phase II Trial. J. Clin. Oncol. 22, 2610-2616 (2004). The first work reporting the activity of a monoclonal antibody to EGFR and chemotherapy in patients with metastatic pancreatic cancer.
70. Kindler, H. L. et al. Bevacizumab plus gemcitabine in patients with advanced pancreatic cancer: Updated results of a multi-center phase II trial. Proc. Am. Soc. Clin. Oncol. 23, A4009 (2004)
71. + T cell effector function and tumor free survival in her-2/neu transgenic mice. J. Immunol. 171, 2161-2169 (2003). Establishes a synergistic effect when combining antigen-specific antibodies and vaccine approaches in preclinical models
72. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689 (1989).
73. Hruban, R. H. et al. K-ras oncogene activation in adenocarcinoma of the pancreas. Am. J. Path. 143, 545-554 (1993).
74. Gjertsen, M. K. et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding ras mutation. Lancet 346, 1399-1400 (1995).
75. Finn, O. J. et al. MUC-1 epithelial tumor mucin-based immunity and vaccines. Immunol. Rev. 145, 61-89 (1995).
76. Apostopopoulos, V. & McKenzie, I. F. Cellular mucins: targets for immunotherapy. Crit. Rev. Immunol. 14, 293-309 (1994).
77. Hammarstrom, S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 9, 67-81 (1999).
78. Achtar, M. et al. Mutant ras vaccine in advanced cancers. Proc. Am. Soc. Clin. Oncol. 22, A677 (2003).
79. Jaffee, E. M. et al. A novel allogeneic GM-CSF secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145-156 (2001). The first work establishing the safety of a GM-CSF-secreting tumour in patients with resected pancreatic cancer.
80. Morse, M. et al. Phase I study of immunization with dendritic cells modified with recombinant fowlpox encoding carcinoembryonic antigen (CEA) and the triad of costimulatory molecules CD54, CD58 and CD80 (rF-CEA(6D)-TRICOM) in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. 23, A2508 (2004).
81. Finn, O. J. et al. A phase Ib study of a MUC1 pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic or biliary tumors. Proc. Am. Soc. Clin. Oncol. 23, A2578 (2004).
82. Marshall, J. L. et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 23, 720-731 (2005).
83. Gilliam, A. D. et al. Randomised double blind placebo controlled multi-centre group sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy. Proc. Am. Soc. Clin. Oncol. 23, A2511 (2004).
84. Harris, J. C. et al. The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas. Cancer Res. 64, 5624-5631 (2004).
85. Laheru, D. A. et al. A feasibility study of a GM-CSF secreting irradiated whole cell allogeneic vaccine (GVAX) alone or in sequence with cytoxan for patients with locally advanced or metastatic pancreatic cancer. Proc. Am. Assoc. Cancer Res. A54 (2004).
86. Takigawa, Y. et al. Anti-tumor effect induced by dendritic cell (DC) based immunotherapy against peritoneal dissemination of the hamster pancreatic cancer. Cancer Lett. 215, 179-186 (2004).
87. Kawakami, Y., Okada, T. & Akada, M. Development of immunotherapy for pancreas cancer. Pancreas 28, 320-325 (2004).
88. Nakatsura, T. et al. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur. J. Immunol 32, 826-836 (2002).
89. Rosenberg, S. A. Progress in human tumour immunology and immunotherapy. Nature 411, 380-384 (2001)
90. Boon, T., et al. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337-365 (1994).
91. Argani, P. et al. Discovery of new markers of cancer through serial analysis of gene expression (SAGE): prostate stem cell antigen (PSCA) is overexpressed in pancreatic adenocarcinoma. Cancer Res. 61, 4320-4324 (2001).
92. Dannull, J. et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res. 60, 5522-5528 (2000).
93. Hassan, R., Bera, T. & Pastan, I. Mesothelin: a new target for immunotherapy. Clin. Cancer Res. 10, 3937-3942 (2004)
94. Swierczynski, S. L. et al. Analysis of novel markers in pancreatic and biliary carcinomas using microarrays. Hum. Path. 35, 357-366 (2004)
95. Argani, P. et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinoma of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression. Clin. Cancer Res. 7, 3862-3868 (2001). Describes the first identification of novel pancreatic cancer antigens identified by SAGE analysis.
96. + T-cell response to a pancreatic-cancer-specific antigen can be generated through cross presentation by a vaccine approach designed to recruit APCs to the vaccine site.
97. Guo, Z. S. & Bartlett, D. L. Vaccinia as a vector for gene delivery. Expert Opin. Biol. Ther. 4, 901-917 (2004).
98. Levy, B., Panicalli, D. & Marshall, J. TRICOM: enhanced vaccines as anticancer therapy. Expert Rev. Vaccines 3, 397-402 (2004).
99. Hodge, J. W., Grosenbach, D. W. & Schlom, J. Vector based delivery of tumor-associated antigens and T cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity. Cancer Defect. Prev. 26, 275-291 (2002).
100. Kochi, S. K., Killeen, K. P. & Ryan, U. S. Advances in the development of bacterial vector technology. Expert Rev. Vaccines. 2, 31-43 (2003).
101. Dietrich, G. et al. Live attenuated bacteria as vectors to deliver plasmid DNA vaccines. Curr. Opin. Mol. Ther. 5, 10-19 (2003).
102. Berd, D., Maguire, H. & Mastrangelo, M. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 46, 2572-2577 (1986).
103. Reilly, R. T. et al. The collaboration of both humoral and cellular HER-2/neu targeted immune responses is required for the complete eradication of HER-2/neu expressing tumors. Cancer Res. 61, 880-883 (2001).
104. Leach, S. D. Mouse models of pancreatic cancer: the fur is finally flying! Cancer Cell 5, 7-11 (2004).
105. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003). This is a seminal paper that describes for the first time a mouse model that recapitulates progressive early invasive pancreas cancer following activation of activated KRAS.
106. Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860 (2004).
107. Xu, D., Xu, Y. & Uberbacher, E. C. Computational tools for protein modeling. Curr. Protein Pept. Sci. 1, 1-21 (2000).
108. Rammensee, H., Bachmann, J., Emmerich, N. P., Bachor, O. A. & Stevanovic, S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219 (1999).